• 1
    Bhimma R, Coovadia HM. Hepatitis B virus-associated nephropathy. Am J Nephrol 2004; 24: 198211.
  • 2
    Johnson RJ, Couser W. Hepatitis B infection and renal disease: clinical, immunopathogenetic and therapeutic considerations. Kidney Int 1990; 37: 66376.
  • 3
    Lee HS, Choi Y, Yu SH, Koh HI, Kim MJ, Ko KW. A renal biopsy study of hepatitis B virus-associated nephropathy in Korea. Kidney Int 1988; 34: 53743.
  • 4
    Hattori S, Furuse A, Matsuda I. Presence of HBe antibody in glomerular deposits in membranous glomerulonephritis is associated with hepatitis B virus infection. Am J Nephrol 1988; 8: 3847.
  • 5
    Lin CY. Hepatitis B virus deoxyribonucleic acid in kidney cells probably leading to viral pathogenesis among hepatitis B virus associated membranous nephropathy patients. Nephron 1993; 63: 5864.
  • 6
    Lai KN, Ho RTH, Tam JS, Lai FMM. Detection of hepatitis B virus DNA and RNA in kidneys of HBV-related glomerulonephritis. Kidney Int 1996; 50: 196577.
  • 7
    Ohba S, Kimura K, Mise M et al. Differential localization of s and e antigens in hepatitis B virus-associated glomerulonephritis. Clin Nephrol 1997; 48: 447.
  • 8
    Lin CY, Lin CC, Chang GJJ, King CC. Defect of cell-mediated immune response against hepatitis B virus: an indication for pathogenesis of hepatitis B virus associated membranous nephropathy. Nephron 1997; 76: 17685.
  • 9
    Xe YH, Fang LJ, Zhang YE, Sheng FY, Zhang XR, Guo MY. In situ hybridization of hepatitis B DNA in hepatitis B-associated glomerulonephritis. Pediatr Nephrol 1998; 12: 11720.
  • 10
    Wang NS, Wu ZL, Zhang YE, Guo MY, Liao LT. Role of hepatitis B virus infection in pathogenesis of IgA nephropathy. World J Gastroenterol 2003; 9: 20048.
  • 11
    Lai KN, Tam JS, Lin HJ, Lai FMM. The therapeutic dilemma of the usage of corticosteroids in patients with membranous nephropathy and persistent hepatitis B virus surface antigenaemia. Nephron 1990; 54: 127.
  • 12
    Ozdamar SO, Gucer S, Tinaztepe K. Hepatitis B virus associated nephropathies: a clinicopathological study in 14 children. Ped Nephrol 2003; 18: 238.
  • 13
    Takaki A, Nakatsuka A, Satou C, Iwata Y, Ikeda H, Fukushima M. A case of focal segmental glomerulosclerosis (FSGS) complicated with chronic hepatitis B and treated with steroid and LDL apheresis. Nippon Jinzo Gakkai Shi 2002; 44: 80612.
  • 14
    Lin CL, Lo S. Treatment of hepatitis B virus-associated membranous nephropathy with adenine arabinoside and thymic extract. Kidney Int 1991; 39: 3016.
  • 15
    De Man RA, Schalm SW, Van Der Heijden AJ, Ten Kate FWJ, Wolff ED, Heijtink RA. Improvement of hepatitis B-associated glomerulonephritis after antiviral combination therapy. J Hepatol 1989; 8: 36772.
  • 16
    Poynard T, Conn HO. The retrieval of randomised clinical trials in liver diseases from the medical literature: a comparison of MEDLARS and manual methods. Control Clin Trials 1985; 6: 2719.
  • 17
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 1778.
  • 18
    Petitti DB. Approaches to heterogeneity in meta-analysis. Statist Med 2001; 20: 362533.
  • 19
    Thompson SG, Higgins JPT. How should meta-regression analyses be undertaken and interpreted? Statist Med 2002; 21: 155973.
  • 20
    Begg CB, Mazumadar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 108898.
  • 21
    Egger M, Smith DG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997; 315: 62934.
  • 22
    Lai KN, Li PKT, Lui SF et al. Membranous nephropathy related to hepatitis B virus in adults. N Engl J Med 1991; 324: 145763.
  • 23
    Lin CY. Treatment of hepatitis B virus-associated membranous nephropathy with recombinant alpha-interferon. Kidney Int 1995; 47: 22530.
  • 24
    Conjeevaram HS, Hoofnagle JH, Austin HA, Park Y, Fried MW, Di Bisceglie AM. Long-term outcome of hepatitis B virus-related glomerulonephritis after therapy with interferon alfa. Gastroenterology 1995; 109: 5406.
  • 25
    Chung DR, Yang WS, Kim SB et al. Treatment of hepatitis B virus associated glomerulonephritis with recombinant human alpha interferon. Am J Nephrol 1997; 17: 1127.
  • 26
    Bhimma R, Coovadia HM, Kramvis A, Adhikari M, Kew MC. Treatment of hepatitis B virus-associated nephropathy in black children. Pediatr Nephrol 2002; 17: 3939.
  • 27
    Tang S, Mac-Moune Lai F, Lui YH et al. Lamivudine in hepatitis B-associated membranous nephropathy. Kidney Int 2005; 68: 17508.
  • 28
    Lisker-Melman M, Webb D, Di Bisceglie A et al. Glomerulonephritis caused by chronic hepatitis B virus infection: treatment with recombinant human alpha-interferon. Ann Int Med 1989; 111: 47983.
  • 29
    Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993; 119: 31223.
  • 30
    Di Bisceglie AM. Long-term outcome of interferon-alpha therapy for chronic hepatitis B. J Hepatol 1995; 22: S657.
  • 31
    Lin CY. Hepatitis B virus-associated membranous nephropathy: clinical features, immunologic profiles, and outcome. Nephron 1990; 55: 3744.
  • 32
    Lai KN, Lai FMM. Clinical features and the natural course of hepatitis B virus-related glomerulopathy in adults. Kidney Int 1991; 35: S405.
  • 33
    Pena A, Debora MJM, Melgosa M, Picazo ML, Navarro M. Membranous nephropathy associated with hepatitis B in Spanish children. Clin Nephrol 2001; 55: 2530.
  • 34
    Knecht GL, Chisari FV. Reversibility of hepatitis B virus-induced glomerulonephritis and chronic active hepatitis after spontaneous clearance of serum hepatitis B surface antigen. Gastroenterology 1978; 75: 11526.
  • 35
    Abbas NA, Pitt MA, Green AT, Solomon LR. Successful treatment of hepatitis B virus associated membranoproliferative glomerulonephritis with alpha interferon. Nephrol Dial Transplant 1999; 14: 12725.
  • 36
    Dhiman RK, Kohli HS, Das G, Joshi K, Chawla Y, Sakhuja V. Remission of HBV-related mesangioproliferative glomerulonephritis after interferon therapy. Nephrol Dial Transplant 1999; 14: 1768.
  • 37
    Connor FL, Rosenberg AR, Kennedy SE, Bohane TD. HBV associated nephrotic syndrome: resolution with oral lamivudine. Arch Dis Child 2003; 88: 4469.
  • 38
    Filler G, Feber J, Weiler G, Le Saux N. Another case of HBV associated membranous glomerulonephritis resolving on lamivudine. Arch Dis Child 2003; 88: 460 [letter].
  • 39
    Kanaan N, Horsmans Y, Goffin E. Lamivudine for nephrotic syndrome related to hepatitis B virus (HBV) infection. Clin Nephrol 2006; 65: 20810.
  • 40
    Okuse C, Yotsuyanagi H, Yamada N et al. Successful treatment of hepatitis B virus-associated membranous nephropathy with lamivudine. Clin Nephrol 2006; 65: 536.
  • 41
    Quan A, Portale A, Foster S, Lavine J. Resolution of hepatitis B virus-related membranoproliferative glomerulonephritis after orthotopic liver transplantation. Pediatr Nephrol 1995; 9: 599602.
  • 42
    Bhimma R, Coovadia HM, Adhikari M, Connolly CA. The impact of the hepatitis B virus vaccine on the incidence of hepatitis B virus-associated membranous nephropathy. Arch Pediatr Med 2003; 157: 102530.
  • 43
    Xu H, Sun L, Zhou LJ, Fang LJ, Sheng FY, Guo YQ. The effect of hepatitis B vaccination on the incidence of childhood HBV-associated nephritis. Pediatr Nephrol 2003; 18: 12169.